

Dr. Elyce Cardonick
Cooper Medical School at Rowan

I just have 2 comments. First we just published a paper on additional taxane exposures if you want to add to the human experience on page 17. Reference

Cardonick E, Bhat A, Gilmandyar D, Somer RA. Maternal and Fetal outcomes of Taxane chemotherapy in breast cancer and ovarian cancer during pregnancy: Case Series and Review of literature. *Annals of Oncology* 00: 1-8, 2012doi:10.1093/annonc/mds170

Secondly I would stress more the risk for cardiotoxicity with idarubicin, page 126. To my knowledge this is the only anthracycline with repeated exposures of transient neonatal cardiomyopathy and I don't see any role for its use in pregnancy if daunorubicin, or doxorubicin preferably is available and as efficacious for the particular cancer requiring treatment.

Elyce